WellSpan Health, an integrated health system in Central Pennsylvania and northern Maryland, US, has partnered with Biofourmis to expand its hospital-level and post-acute care at-home programme.
Biofourmis, a technology-enabled care delivery company, will support the enterprise-wide expansion and management of WellSpan’s bundled programme.
Go deeper with GlobalData
This collaboration will see WellSpan replacing its existing system with Biofourmis’s remote patient management solution, which is designed to cover the entire care continuum.
The new solution is highly configurable, supporting patients with various diseases and acuity levels through a range of integrated devices.
Biofourmis’s platform features FDA-cleared algorithms for delivering clinical insights. It also provides automated prompts that can enhance nurse-to-patient ratios and patient volumes.
Biofourmis highlighted that its platform is interoperable with WellSpan’s Epic electronic medical record (EMR) system.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThis interoperability is aimed at providing a unified user experience, enhancing patient management, simplifying patient onboarding, and ensuring consistent clinical information sharing, including billing documentation.
WellSpan will continue work with Biofourmis’ in-house team to further expand the current EMR-centric workflows.
Patients in the hospital-at-home programme are expected to be admitted for up to seven days and may receive periodic monitoring and post-discharge care for up to 30 days.
The artificial intelligence (AI)-powered clinical insights provided by Biofourmis’s platform will be crucial for proactive care, using continuous or episodic data from wearable biosensors, as well as patient-reported outcomes from mobile devices.
The partnership is further projected to increase hospital-level and post-acute care-at-home patient volume by 75% over the next three years, potentially easing clinician workloads through automation.
WellSpan anticipates that this expansion will maximise bed availability for more critical cases, minimise readmission rates, and improve patient outcomes.
Metrics such as emergency department visits and hospital readmissions will be monitored, along with patient experiences and chronic condition management, to assess the impact of the home care programme.
Biofourmis chief medical officer and co-founder Maulik Majmudar said: “WellSpan Health is an innovative health system, with a clear care-at-home vision and strategy. They recognise that a single, comprehensive care solution that enables scalable outcomes based on their unique needs during their care-at-home evolution is essential for driving a thriving programme.”
